1. Human Aging ResearchPasswater, Richard A. and Welker, Paul A.Amer. Lab. 3(5):21-6 (May 1971)

2. Pharmokinetics of oral acetylcysteine.Rodenstein, D., DeCoster, A. and Gazzaniga, A.Clin. Pharmacokin. 3:247-54 (1978)

3. Toxicological, pharmacokinetics and metabolic studies onacetylcysteine.Bonanomi, L. and Gazzaniga, A.Eur. J. Respir. Dis. 61(Sup):45-51 (1980)

4. Clinical pharmacokinetics of N-acetylcysteine.Borgstrom, L., Kagedal, B. and Paulsen, O.Eur. J. Clin. Pharmacol. 31:217-22 (1986)

5. Pharmokinetics and bioavailability of reduced and oxidizedN-acetylcysteine.Olsson, B., et al.Eur. J. Clin. Pharmocol. 34:77-82 (1988)

6. Acetylcysteine: A drug that is much more than a mucokinetic.Ziment, I.Biomed. Pharmacother. 42:513-20 (1988)

7. Pharmacokinetics and bioavailability of oral acetylcysteinein healthy volunteers.De Caro, L., et al.Arzneim.-Forsch/Drug Res., 39:382 (1989)

8. Suppression of Cytokine-induced Human Immunodeficiency Virus(HIV) expression by N-acetylcysteine (NAC), glutathione(GSH) and Glutathione monoester (GSE)Kinter, Audrey L., et al.75th Annual Meeting of the Federation of American Societiesfor Experimental Biology, Atlanta, Georgia (April 21-5, 1991)J. FASEB 5(5) A1265 (1991)

9. Suppression of human immunodeficiency virus expression inchronically infected monocytic cells by glutathione,glutathione ester, and N-acetylcysteine. Kalebic, Thea, et al.Proc. Natl. Acad. Sci. 88(3):986-90 (1991)

10. Thiol-based compounds may limit AIDS progression.CDC AIDS Weekly p3 (Feb. 25, 1991)

11. Cytokine-stimulated human immunodeficiency virus replicationis inhibited by N-acetylcysteine.Roederer, M., et al.Proc. Natl. Acad. Sci. 87:4884-8 (1990)

12. Reducing agents and AIDS - Why are we waiting?Turner, V. F.Med. J. Aust. 153/8, 502 (1990)

13. Mercaptoethanol and N-acetylcysteine enhance T-cell colonyformation in AIDS and ARC. Wu, J., et al.Clin. Exp. Immunol. 77/1, 7-10 (1989)

14. AIDS - Drug therapy; Acetylcysteine research.Cooper, MikeCDC AIDS Weekly p4 (Oct. 2, 1989)

15. Glutathione deficiency and radiosensitivity in AIDSpatients.Vallis, K. A.The Lancet 337:918-9 (April 13, 1991)

16. Lipoprotein(a) reduction by N-acetylcysteine.Gavish, Dov and Breslow, Jan L.The Lancet 337:203-4 (Jan. 26, 1991)

17. N-acetylcysteine and lipoprotein.Stalenhoef, A. F. H., et al.The Lancet 337:491 (1991)

18. AcetylcysteineEditorialThe Lancet 337(8749):1069-70 (May 4, 1991)

19. N-Acetylcysteine and immunoreactivity of lipoprotein(a).Scanu, Angelo M.The Lancet 337:1159 (May 4, 1991)

20. Metabolic disorder as early consequence of SimianImmunodeficiency Virus infection in Rhesus macaques.Eck, Hans-Peter, et al.Lancet 338:346-7 (Aug. 10, 1991)

21. Mercaptoethanol and N-acetylcysteine enhance T-cell colonyformation in AIDS and ARC.Wu, J., Levy, E. M. and Black, P. H.Clin. Exp. Immunol. 77:7-10 (1989)

22. Clinical application for heavy metal-complexing potential ofN-acetylcysteine.Lorber, A., et al.J. Clin. Pharmacol. 13:332-6 (1973)

23. Treatment of acute methylmercury ingestion byhemodialysis with N-acetylcysteine.Lund, M. E., Clarkson, T. W. and Berlin, M.J. Toxicol. Clin. Toxicol. 22:31-49 (1984)